Repository logo
 
Publication

Disclosure of a promising lead to tackle complicated skin and skin structure infections : antimicrobial and antibiofilm actions of peptide PP4-3.1

datacite.subject.fosCiências Médicas
datacite.subject.sdg03:Saúde de Qualidade
dc.contributor.authorGomes, Ana
dc.contributor.authorBessa, Lucinda J.
dc.contributor.authorFernandes, Iva
dc.contributor.authorFerraz, Ricardo
dc.contributor.authorMonteiro, Cláudia
dc.contributor.authorMartins, M. Cristina L.
dc.contributor.authorMateus, Nuno
dc.contributor.authorGameiro, Paula
dc.contributor.authorTeixeira, Cátia
dc.contributor.authorGomes, Paula
dc.date.accessioned2025-09-17T15:09:20Z
dc.date.available2025-09-17T15:09:20Z
dc.date.issued2021-11
dc.description.abstractEfficient antibiotics are being exhausted, which compromises the treatment of infections, including complicated skin and skin structure infections (cSSTI) often associated with multidrug resistant (MDR) bacteria, methicillin-resistant S. aureus (MRSA) being the most prevalent. Antimicrobial peptides (AMP) are being increasingly regarded as the new hope for the post-antibiotic era. Thus, future management of cSSTI may include use of peptides that, on the one hand, behave as AMP and, on the other, are able to promote fast and correct skin rebuilding. As such, we combined the well-known cosmeceutical pentapeptide-4 (PP4), devoid of antimicrobial action but possessing collagenesis-boosting properties, with the AMP 3.1, to afford the chimeric peptide PP4-3.1. We further produced its N-methyl imidazole derivative, MeIm-PP4-3.1. Both peptide-based constructs were evaluated in vitro against Gram-negative bacteria, Gram-positive bacteria, and Candida spp. fungi. Additionally, the antibiofilm activity, the toxicity to human keratinocytes, and the activity against S. aureus in simulated wound fluid (SWF) were assessed. The chimeric peptide PP4-3.1 stood out for its potent activity against Gram-positive and Gram-negative bacteria, including against MDR clinical isolates (0.8 ≤ MIC ≤ 5.7 µM), both in planktonic form and in biofilm matrix. The peptide was also active against three clinically relevant species of Candida fungi, with an overall performance superior to that of fluconazole. Altogether, data reveal that PP4-3.1 is as a promising lead for the future development of new topical treatments for severe skin infections.eng
dc.identifier.citationGomes A, Bessa LJ, Fernandes I, Ferraz R, Monteiro C, L. Martins MC, Mateus N, Gameiro P, Teixeira C, Gomes P. Disclosure of a Promising Lead to Tackle Complicated Skin and Skin Structure Infections: Antimicrobial and Antibiofilm Actions of Peptide PP4-3.1. Pharmaceutics. 2021; 13(11):1962. https://doi.org/10.3390/pharmaceutics13111962
dc.identifier.doi10.3390/pharmaceutics13111962
dc.identifier.issn1999-4923
dc.identifier.urihttp://hdl.handle.net/10400.26/58705
dc.language.isoeng
dc.peerreviewedyes
dc.publisherMDPI
dc.relation.hasversionhttps://doi.org/10.3390/pharmaceutics13111962
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectantibacterial
dc.subjectantibiofilm
dc.subjectantifungal
dc.subjectantimicrobial peptides
dc.subjectcollagen
dc.subjectmultidrug resistance
dc.subjectskin infections
dc.subjectwound healing
dc.titleDisclosure of a promising lead to tackle complicated skin and skin structure infections : antimicrobial and antibiofilm actions of peptide PP4-3.1eng
dc.typecontribution to journal
dspace.entity.typePublication
oaire.citation.issue11
oaire.citation.startPage1962
oaire.citation.titlePharmaceutics
oaire.citation.volume13
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Artigo_LBessa_2021_01.pdf
Size:
3.29 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.85 KB
Format:
Item-specific license agreed upon to submission
Description: